Introduction
============

Colorectal cancer (CRC) is the third most common cancer type and the fourth leading cause of cancer-related deaths in the world. Traditionally, CRC was more prevalent in developed countries, while its incidence and mortality has been also on the rise in developing countries over recent decades [@B1], [@B2]. Therefore, many efforts have been devoted in recent years to improve the efficacy of clinical treatment of CRC. However, great histological and molecular heterogeneity has become a major obstacle for effective prognostication and treatment stratification, raising challenges for clinical management. Recent studies have proposed that a significant part of this heterogeneity is captured by the anatomical location of the tumor.

From the perspective of embryologic development, the right- and left-sided colon have different developmental origin. The right colon arises from the midgut and the left colon from the hindgut, which are exposed to different luminal environment[@B3]. Accordingly, right- and left-sided CRC differs in demographical and clinical features. Furthermore, genetic studies have revealed differential gene expression patterns and gene mutation landscape between right- and left-sided colon cancers[@B4], [@B5]. For these biological and molecular distinctions, the prognostic value of primary tumor location (PTL) in CRC has been proposed and attracted much attention especially in recent 10 years. On the whole, right-sided tumors was associated with a worse prognosis than left-sided tumors irrespective of tumor stages from several population-based studies worldwide[@B6]-[@B10]. However, evidences from these studies also suggested that the prognostic value of PTL seemed to be tumor stage specific. In detail, for early-stage stage (I-II) CRC, similar prognosis was found between right-sided and left-sided CRCs[@B11], [@B12]. For stage III CRC, it was found that right-sided tumors begin to show significantly worse prognosis than left-sided CRCs[@B11], [@B13]. Then for unresectable stage IV CRC (mCRC), existing results supported that right-sided PTL was also associated with higher mortality regardless of chemotherapy alone or in combination with targeted therapy (BT) (eg, bevacizumab or cetuximab) [@B14]-[@B19]. More recently, the role of PTL in predicting response to anti-EGFR based therapy in mCRC became a hotspot. In patients with wild-type KRAS tumors, treatment with cetuximab may possibly benefit only those with left-sided mCRC but not right-sided cases as recent researches have indicated.[@B20]-[@B25]. These evidences supports the conclusion that patients with left-sided RAS wild-type mCRC should be preferentially treated with an anti-EGFR antibody, while in right-sided mCRC, anti-EGFR therapy is not recommended.

As a unique clinical phase of mCRC, synchronous colorectal liver metastasis (sCRLM) has attracted more and more attention. In recent years, the development of treatment concept and surgical techniques has led to revolutionary changes in clinical management of sCRLM, and it is generally accepted that surgical resection of both primary tumor and liver metastases is the only curative treatment strategy for sCRLM. However, the resection for cure is performed significantly less often in cases of sCRLM than for metachronous metastases cases (6.3% vs 16.9%, respectively), and the 5-year survival rates were lower with synchronous than with metachronous cases (3.3% vs 6.1%, respectively)[@B26]. To date, studies concerning the prognostic value of PTL in sCRLM after resection are limited, especially in those who have metastases confined to the liver. The existing studies were mostly based on single center experience, and all of them both included synchronous and metachronous CRLM cases for study[@B27]-[@B31]. Thus, it remains unclear whether the prognosis of sCRLM with right-sided PTL is different from left-sided cases. Here we used population-based data from the SEER database, to analyze the association between PTL and prognostic survival especially in sCRLM after surgical treatment.

Methods
=======

Data source
-----------

Data was obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The current SEER database consists of 18 population-based cancer registries that cover approximately 28% of cancer cases in the United States. This database contains no personal identifiers and is publicly available for cancer studies. And this study was also approved by our institutional review board at Huashan Hospital, Fudan University.

Cohort definition
-----------------

We used the National Cancer Institute SEER\*Stat software (Version 8.3.2, <http://seer.cancer.gov/seerstat>) to identify patients. Firstly, patients with CRC were identified with the following inclusion criteria: [@B1] International Classification of Diseases for Oncology (ICD-O) code 8936; [@B2] the year of diagnosis ranged from 2010 to 2014; [@B3] diagnosis was confirmed by histology; [@B4] aged 18 or older; [@B5] the cause of death and survival time were both known. Then a stringent exclusive procedure was performed to identify CRC cases with liver-limited metastases. The detailed procedure for patient selection is outlined in Figure [1](#F1){ref-type="fig"}.

Parameters
----------

The following parameters were extracted from the SEER database, including sex, age, race, grade, year of diagnosis, marital status, insurance status, primary tumor location, histological type, grade, primary tumor size, neural invasion, lymph node status, tumor deposit and resection margin. The main parameter of interest was each patient\'s PTL at diagnosis. The division in the right- and left-sided CRC is based on its embryological origin. The embryological border between both parts of the colon is located at the proximal two-thirds of the transverse colon. However, most researchers use the splenic flexure as the demarcation line between right- and left-sided tumors [@B32]. In our study, the right-sided CRC includes those originate from caecum, ascending colon, hepatic flexure and transverse colon, while the left part consists of the splenic flexure, descending colon, sigmoid and rectum.

The main outcomes were 5-year overall survival (OS) and cancer specific survival (CSS). CSS was defined from the date of diagnosis to the date of cancer specific death. In this study, CSS was defined as death due to sCRLM, excluding other causes of death.

Statistical analysis
--------------------

Clinicopathological parameters were analyzed by chi-square (χ2) test. Kaplan-Meier plots were used to show OS and CSS, and the differences were analyzed by log-rank test. Multivariate Cox proportional hazard models were adopted to analyze the risk factors of survival outcomes. All data analyses were performed using statistical software package SPSS (version 19.0, Inc, Chicago, IL, USA). All statistical tests were evaluated using a two tailed 95% confidence interval (CI), and a two-side P value of less than 0.05 was set for statistical significance.

Results
=======

Patient enrollment, selection and characteristics of the study cohort
---------------------------------------------------------------------

In the initial enrollment stage, 22102 patients diagnosed as CRC from 2010 to 2014 were included. Then we conducted a stringent exclusion procedure as shown in Figure [1](#F1){ref-type="fig"}. We further grouped the patients based on information about metastasis, primary lesion and surgery as stated in Figure [1](#F1){ref-type="fig"}. Ultimately, 1508 patients in cohort A were selected for our study. Demographics of the 1508 subjects included in the study are listed in Table [1](#T1){ref-type="table"}. The median age of the 1508 selected subjects was 61 year old (19-97), and most of them were white (75.9%, 𝑛 =1145) and male (57.8%, 𝑛=872). On pathological types, the majority of patients were adenocarcinoma (93.6%, 𝑛 =1412). Of subjects with known lymph nodal status, most had N1 lymph node involvement (44.2%), with 19.1% having N0 and 36.0% having N2 disease. With respect to PTL, 593 (39.3%) had right-sided tumors and 915 (60.7%) had left sided tumors, including 358 (23.7%) rectal cancer.

Comparison of clinicopathological features between right-sided and left-sided CRC with synchronous liver-limited metastases
---------------------------------------------------------------------------------------------------------------------------

Then we compared the clinicopathological features between right-sided and left-sided sCRLM in cohort A cases**.** As shown in Table [1](#T1){ref-type="table"}, patients originating from right-sided tumors showed different baseline characteristics from left-sided cases in gender (male, 51.8% vs. 61.7%, p\<0.001), age (≥60 year, 65.3% vs. 48.3%, p\<0.001), race (black, 18.7% vs. 11.1%, p\<0.001) and marital status (widowed, 13.3% vs. 6.2%, p\<0.001). In clinicopathological parameters, the right-sided tumors showed significantly higher proportion of poor differentiation or undifferentiated (30.5% vs. 15.1%, p\<0.001), mucinous change (7.3 % vs. 4.0%, p=0.005), T4 (31.3% vs. 20.1%, p\<0.001) and N2 (42.5% vs. 31.8%, p\<0.001) status, but lower occurrence of neural invasion (22.1% vs. 28.5%, p=0.009), compared with originally left-sided tumors. Meanwhile, more lymph nodes (LN) were examined perioperatively in cases of right-sided sCRLM compared with left-sided cases (\>12 LN, 88.7% vs. 81.0%, p\<0.001). Otherwise, the two subgroups did not show significant differences in proportion of CEA positive, resection margin or tumor deposits.

Survival analysis based on primary tumor location
-------------------------------------------------

To determine whether the primary tumor location is associated with distinct clinical outcomes in sCRLM, we then evaluated the prognosis of the two subsite in our cohort. Of note, Kaplan-Meier plots of 5-year CSS were significantly worse in patients with right-sided sCRLM (Figure [2](#F2){ref-type="fig"}, p\<0.001), and left-sided colon cancer and rectal cancer showed similarly better CSS (Figure [3](#F3){ref-type="fig"}, p\<0.001). Consistently, Kaplan-Meier survival curve based on more detailed tumor subsite location are presented in Supplementary Figure [1](#SM0){ref-type="supplementary-material"}. Splenic flexure, sigmoid colon and rectal cases had the highest overall survival estimates, descending and transverse colon cancers had intermediate survival estimates, whereas proximal cancers had the poorest survival.

Multivariate analysis of factors associated with Mortality
----------------------------------------------------------

Next, we evaluated the association of clinicopathological factors with the outcome of sCRLM patients. On multivariable analyses after controlling for competing risk factors, several factors remained independently associated with OS and CSS, including old age (≥80) (OS, HR= 3.5, 95% CI 2.04-6.02; CSS, HR= 3.31, 95% CI 1.87-5.87), N2 status (OS, HR= 1.54, 95% CI 1.02-2.31; CSS, HR=1.73, 95% CI 1.11-2.71), resection margin (OS, HR= 1.83, 95% CI 1.29-2.59; CSS, HR=1.89, 95% CI 1.32-2.71), as well as right-sided PTL (OS, HR= 1.75, 95% CI 1.34-2.29; CSS, HR=1.76, 95% CI 1.33-2.35) (all P\<0.05). While other factors such as gender, race, marital status, insurance status, CEA positive, tumor size, tumor deposit, histological type, differentiation, neural invasion and T status were not correlated with OS or CSS in this cohort (Table [2](#T2){ref-type="table"}).

Discussion
==========

During the last years, the impact of PTL in CRC has been intensively studied by multiple research groups. Now it has been recognized that the right- and left-sided CRC have different developmental origin and correspondingly diverse oncogenic mechanism, contributing to side specific clinical outcome and therapeutic response[@B4], [@B5], [@B32]. However, whether this prognostic distinction also exists in specific clinical stages of CRC remains obscure. In this study, using the SEER database, we confirmed the emerging notion that in stage IVA CRC with liver-limited metastases, right-sided PTL also predict worse prognosis than left-sided tumors, for cases who accepted surgical treatment of both primary and hepatic metastases.

The mechanism that contributed to the great prognostic discrepancy between right- and left-sided CRC has been intensively investigated. Demographically, right-sided tumors differ in gender, age and race compared to left-sided cases. Furthermore, CRC in patients over 80s are far more likely to be in the right-sided colon, as is shown in our study. Clinically, right-sided sCRLM appears to have an intent of low differentiated degrees, larger size of primary lesion and early lymph nodes invasion, indicating its relative higher malignancy degrees, which can also partly explain its negative significance in prognosis. Biologically, the differences in luminal content and bacterial flora between the right- and left-sided colon may also influence tumor biology and prognosis[@B32]. Additionally on molecular level, right-sided carcinomas are more often KRAS/BRAF-mutated, more enriched in microsatellite instability (MSI), CpG island methylation phenotype (CIMP) and CMS1 molecular subtype. Left-sided tumors more often harbor chromosomal instability (CIN) and CMS2 molecular subtype[@B5], [@B32]. Based these evidences, it is convincingly suggested that the above clinical and molecular parameters converged to contribute to the prognostic distinction between right- and left-sided sCRLM.

In recent three years, there have been several studies focusing on the association between PTL and prognostic survival in CRLM after surgical treatment based on single center data. In 2016, Sasaki K from Johns Hopkins Hospital firstly reported the prognostic implications of PTL in CRLM undergoing resection. Of note, patients with left-sided primary tumor had a shorter RFS compared with patients who had a right-sided tumor, while right-sided primary CRC tumors had a shorter OS compared with left-sided tumors[@B27]. Interestingly, their subsequent study revealed a differential prognostic implication of KRAS status after hepatectomy for CRLM according to PTL. Among patients with a right-sided CRC, 5-year RFS and OS were not correlated with KRAS status. In contrast, among patients from a left-sided primary CRC, 5-year RFS and OS were worse among patients with mutant-type KRAS[@B33]. Similarly, experience from MD Anderson Cancer Center found that both RFS and OS after hepatic resection were worse in patients with midgut origin tumors (right-sided)[@B28]. Then data from MSKCC showed that right-sided CRLM had significantly worse OS compared to left-sided CRLM after resection, while the median RFS was only marginally different[@B29]. Consistently, a study from Europe found that right-sided PTL is associated with worse OS after surgery for CLM, but seems to have no influence on PFS[@B30]. However, two recent study from Brazil and China reported that PTL did not affect OS or DFS for patients with resected CRLM[@B31], [@B34]. All the above studies in combination with our study indicate that PTL is an important prognostic factor for OS, while its role in RFS/PFS/DFS is still controversial.

Traditionally, the clinical prognostication of sCRLM after surgical treatment has long been relegated to clinical staging/scoring system[@B35]-[@B39] or nomograms[@B40]. A major clinically relevant finding of this study is that prognostication of sCRLM based on PTL may be predictive of prognosis (OS and RFS) and is clinically applicable. Our results indicated that adding PTL may provide an important optimization for currently used sCRLM prognosis prediction models.

Compared to the published studies including both synchronous and metachronous CRLM, our present study mainly focused on sCRLM, which further reduced the heterogeneity. However, the limitations of our study are obvious for its nature of retrograde cohort study. Primarily, all the patients enrolled were diagnosed between 2010 and 2014 from diverse medical institutions, which means there is no standard evaluation on surgical resections, providing a confounding factor. Moreover, information about the liver metastases retrieved from the SEER database is limited, such as the number and largest size of liver lesions.

Conclusively, for sCRLM patients underwent surgical resection on both primary tumor and liver metastases, PTL can act as an effectively predictive indicator for prognosis. In the future, selectively prognostic and therapeutic stratification may be suggested in clinical practice for right- and left-sided sCRLM.
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###### 

Baseline clinicopathological characteristics of patients with differed sCRLM locations in SEER database

  ---------------------------------------------------------------------------------------------------------------------
  \                                                      Primary tumor location                               
  Characteristic                                                                                              
  ------------------------------------------------------ ------------------------ ------------- ------------- ---------
  **Patient Related**                                                                                         

  **Sex**                                                                                                     

  Female                                                 636 (42.2%)              286 (48.2%)   350 (38.3%)   \<0.001

  Male                                                   872 (57.8%)              307(51.8%)    565 (61.7%)   

  **Age at diagnosis (years)**                                                                                

  median/mean                                            61/60.9                                              

  \<50                                                   285 (18.9%)              77 (13.0%)    208 (22.7%)   \<0.001

  50-59                                                  395 (26.2%)              129 (21.8%)   266 (29.1%)   

  60-69                                                  440 (29.2%)              183 (30.9%)   257 (28.1%)   

  70-79                                                  266 (17.6%)              124 (20.9%)   142 (15.5%)   

  ≥80                                                    122 (8.1%)               80 (13.5%)    42 (4.7%)     

  **Race**                                                                                                    

  White                                                  1145 (75.9%)             446 (75.2%)   699 (76.4%)   \<0.001

  Black                                                  213 (14.1%)              111 (18.7%)   102 (11.1%)   

  Other                                                  148 (9.8%)               36 (6.1%)     112 (12.2%)   

  Unknow                                                 2 (0.1%)                 0 (0%)        2 (0.2%)      

  **Marital status**                                                                                          \<0.001

  Married                                                904 (59.9%)              340 (57.3%)   564 (61.6%)   

  Widowed                                                136 (9.0%)               79 (13.3%)    57 (6.2%)     

  Single, separated, or divorced                         400 (26.5%)              149 (25.1%)   251 (27.4%)   

  Unknown                                                68 (4.5%)                25 (4.2%)     43 (4.7%)     

  **Insurance status**                                                                                        0.029

  Insured                                                1253 (83.1%)             509 (85.8%)   744 (81.3%)   

  Any Medicaid                                           178 (11.8%)              54 (9.1%)     124 (13.6%)   

  Uninsured                                              57 (3.8%)                24 (4.0%)     33 (3.6%)     

  unknown                                                20 (1.3%)                6 (1.0%)      14 (1.5%)     

  **Disease Related**                                                                                         

  **CEA level**                                                                                               0.623

  Positive/elevated                                      840 (55.7%)              317 (53.5%)   523 (57.2%)   

  Negative/normal                                        287 (19.0%)              113 (19.1%)   174 (19.0%)   

  Unknown/Borderline                                     381 (25.3%)              163 (27.5%)   218 (23.8%)   

  **Primary tumor size (mm)**                                                                                 

  ≤50                                                    777 (51.5%)              301 (50.8%)   510 (55.6%)   0.003

  \>50                                                   408 (27.1%)              270 (45.5%)   332 (36.3%)   

  **Tumor deposits**                                                                                          0.27

  Yes                                                    393 (26.1%)              146 (24.6%)   247 (27.0%)   

  No                                                     1036 (68.7%)             418 (70.5%)   618 (67.5%)   

  Unknown                                                79 (5.2%)                29 (4.9%)     50 (5.5%)     

  **Tumor differentiation(grade)**                                                              \<0.001       

  Undifferentiated (IV)                                  68 (4.5%)                40 (6.7%)     28 (3.1%)     

  Poor (III)                                             251 (16.6%)              141 (23.8%)   110 (12.0%)   

  Moderate (II)                                          1072 (71.1%)             373 (62.9%)   699 (76.4%)   

  Well (I)                                               40 (2.7%)                15 (2.5%)     25 (2.7%)     

  Unknown                                                77 (5.1%)                24 (4.0%)     53 (5.8%)     

  **Histological subtype**                                                                                    0.005

  Adenocarcinoma                                         1412 (93.6%)             540 (91.1%)   872 (95.3%)   

  Mucinous adenocarcinoma                                80 (5.3%)                43 (7.3%)     37 (4.0%)     

  Other                                                  16 (1.1%)                10 (1.7%)     6 (0.7%)      

  **Neural invasion**                                                                                         0.009

  Yes                                                    392 (26.0%)              131 (22.1%)   261 (28.5%)   

  No                                                     991 (65.7%)              407 (68.6%)   584 (63.8%)   

  Unknown                                                125 (8.3%)               55 (9.3%)     70 (7.7%)     

  **Resection Margin**                                                                                        0.484

  R0                                                     993 (65.8%)              387 (65.3%)   606 (66.2%)   

  R1                                                     140 (9.3%)               59 (9.9%)     81 (8.9%)     

  Unknown                                                375 (24.9%)              147 (24.8%)   228 (24.9%)   

  **T status**                                                                                                \<0.001

  T1                                                     24 (1.6%)                3 (0.5%)      21 (2.3%)     

  T2                                                     62 (4.1%)                24 (4.0%)     38 (4.2%)     

  T3                                                     1020 (67.6%)             372 (62.7%)   648 (70.8%)   

  T4a                                                    274 (18.2%)              133 (22.4%)   141 (15.4%)   

  T4b                                                    96 (6.4%)                53 (8.9%)     43 (4.7%)     

  Unknown                                                32 (2.1%)                8 (1.3%)      24 (2.6%)     

  **Nodal status**                                                                                            \<0.001

  NX                                                     11 (0.7%)                2 (0.3%)      9 (1.0%)      

  N0                                                     288 (19.1%)              93 (15.7%)    195 (21.3%)   

  N1                                                     666 (44.2%)              246 (41.5%)   420 (45.9%)   

  N2                                                     543 (36.0%)              252 (42.5%)   291 (31.8%)   

  **Adequate lymph node examination (i.e., 12 nodes)**                            \<0.001                     

  No                                                     224 (14.9%)              58 (9.8%)     166 (18.1%)   

  Yes                                                    1267 (84.0%)             526 (88.7%)   741 (81.0%)   

  Unknown                                                17 (1.1%)                9 (1.5%)      8 (0.9%)      
  ---------------------------------------------------------------------------------------------------------------------

###### 

Survival analysis of subgroups based on clinicopathological characteristics

  Variable                     Overall Survival                       Cancer-Specific Survival                                          
  ---------------------------- ------------------ ------------------- -------------------------- -- ---------------- ------------------ ---------
  **Sex**                                                                                                                               
  female                       247/21 (36.0%)     1 \[Reference\]                                   232/21 (37.9%)   1 \[Reference\]    
  male                         328/32 (32.6%)     0.85 (0.65-1.11)    0.232                         292/42 (38.1%)   0.79 (0.60-1.05)   0.104
  **Race**                                                                                                                              
  White                        428/34 (34.9%)     1 \[Reference\]                                   390/34 (39.0%)   1 \[Reference\]    
  Black                        100/10 (26.6%)     1.11 (0.77-1.59)    0.581                         91/10 (29.9%)    1.07 (0.73-1.57)   0.741
  Other                        47/8 (39.3%)       1.08 (0.68-1.69)    0.756                         43/8 (42.0%)     0.99 (0.61-1.61)   0.972
  **Age**                                                                                                                               
  \<50                         81/10 (40.9%)      1 \[Reference\]                                   77/10 (41.8%)    1 \[Reference\]    
  50-59                        124/29 (41.0%)     0.77 (0.48-1.22)    0.266                         116/29 (42.7%)   0.76 (0.47-1.24)   0.271
  60-69                        165/23 (35.2%)     1.29 (0.85-1.93)    0.23                          149/23 (40.2%)   1.30 (0.85-2.00)   0.226
  70-79                        124/10 (27.6%)     1.89 (1.22-2.92)    0.004                         111/14 (35.6%)   1.86 (1.18-2.96)   0.008
  ≥80                          81/1 (7.6%)        3.5 (2.04-6.02)     \<0.001                       71/1 (9.6%)      3.31 (1.87-5.87)   \<0.001
  **Marital status**                                                                                                                    
  Married                      306/53 (38.7%)     1 \[Reference\]                                   277/53 (42.5%)   1 \[Reference\]    
  Widowed                      77/9 (23.0%)       0.89 (0.56-1.41)    0.612                         69/9 (26.7%)     0.86 (0.53-1.39)   0.531
  Single/Separated/divorced    167/13 (30.1%)     1.27 (0.94-1.71)    0.127                         156/13 (33.5%)   1.26 (0.92-1.73)   0.155
  **Insurance status**                                                                                                                  
  Uninsured                    24/5 (31.4%)       1 \[Reference\]                                   23/5 (32.2%)     1 \[Reference\]    
  Insured                      470/37 (34.8%)     0.66 (0.35-1.23)    0.192                         425/37 (39.0%)   0.65 (0.34-1.25)   0.197
  Any Medicaid                 76/9 (30.3%)       1.15 (0.57-2.35)    0.694                         71/9 (32.3%)     1.20 (0.57-2.53)   0.631
  **CEA level**                                                                                                                         
  Negative                     83/21 (51.3%)      1 \[Reference\]                                   78/21 (52.8%)    1 \[Reference\]    
  Positive                     333/23 (29.4%)     1.38 (0.99-1.92)    0.056                         300/23 (34.3%)   1.37 (0.97-1.93)   0.078
  **Tumor size**                                                                                                                        
  \<50                         238/19 (35.1%)     1 \[Reference\]                                   218/19 (37.5%)   1 \[Reference\]    
  ≥50                          303/37 (31.6%)     1.11 (0.86-1.44)    0.431                         278/37 (35.3%)   1.17 (0.89-1.54)   0.251
  **Tumor deposits**                                                                                                                    
  Negative                     361/35 (38.6%)     1 \[Reference\]                                   326/35 (42.5%)   1 \[Reference\]    
  Positive                     169/13 (27.6%)     1.30 (0.98-1.73)    0.071                         160/13 (29.9%)   1.31 (0.97-1.77)   0.074
  **Histological subtype**                                                                                                              
  Mucinous adenocarcinoma      34/4 (27.8%)       1 \[Reference\]                                   32/4 (32.0%)     1 \[Reference\]    
  Adenocarcinoma               534/42 (34.4%)     1.13 (0.64-1.98)    0.68                          485/42 (38.4%)   1.14 (0.63-2.06)   0.663
  **Differentiation**                                                                                                                   
  Well differentiated          16/7 (37.0%)       1 \[Reference\]                                   15/7 (39.5%)     1 \[Reference\]    
  Moderately differentiated    372/32 (36.0%)     1.16 (0.52-2.59)    0.711                         334/32 (40.5%)   1.01 (0.45-2.26)   0.984
  Poorly differentiated        131/9 (24.3%)      2.03 (0.86-4.78)    0.106                         123/9 (26.9%)    1.81 (0.76-4.32)   0.179
  Undifferentiated             37/4 (18.2%)       1.79 (0.69-4.67)    0.235                         34/4 (20.6%)     1.58 (0.60-4.20)   0.357
  **Neural invasion**                                                                                                                   
  Negative                     352/29 (37.3%)     1 \[Reference\]                                   320/29 (40.4%)   1 \[Reference\]    
  Positive                     161/19 (28.6%)     1.063 (0.79-1.43)   0.684                         149/19 (31.3%)   1.08 (0.80-1.48)   0.615
  **T status(no/yes)**                                                                                                                  
  T1                           7/9 (57.0%)        1 \[Reference\]                                   6/9 (62.7%)      1 \[Reference\]    
  T2                           17/11 (49.7%)      0.73 (0.09-5.91)    0.766                         16/11 (52.4%)    0.58 (0.07-4.76)   0.608
  T3                           361/35 (36.9%)     0.87 (0.12-6.38)    0.888                         320/35 (41.8%)   0.67 (0.09-4.99)   0.699
  T4                           180/10 (21.9%)     0.81 (0.11-6.06)    0.834                         172/10 (23.2%)   0.69 (0.09-5.18)   0.714
  **Nodal status**                                                                                                                      
  N0                           83/40 (52.4%)      1 \[Reference\]                                   73/44 (57.1%)    1 \[Reference\]    
  N1                           240/16 (33.2%)     1.23 (0.84-1.81)    0.296                         218/16 (36.0%)   1.37 (0.90-2.09)   0.146
  N2                           249/24 (26.5%)     1.54 (1.02-2.31)    0.04                          230/30 (30.8%)   1.73 (1.11-2.71)   0.015
  **Resection Margin**                                                                                                                  
  Negative                     343/29 (35.2%)     1 \[Reference\]                                   303/29 (39.8%)   1 \[Reference\]    
  Positive                     82/10 (21.2%)      1.83 (1.29-2.59)    0.001                         79/10 (21.9%)    1.89 (1.32-2.71)   \<0.001
  **Primary tumor location**                                                                                                            
  Left-sided                   289/55 (40.1%)     1 \[Reference\]                                   261/59 (44.8%)   1 \[Reference\]    
  Right-sided                  286/9 (24.6%)      1.75 (1.34-2.29)    \<0.001                       263/9 (26.8%)    1.76 (1.33-2.35)   \<0.001
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